A Real-World Analysis of Relapse Rate and Efficacy of a Restricted Monthly Dose of Omalizumab in Recalcitrant Chronic Spontaneous Urticaria in India

Detalles Bibliográficos
Autores principales: Sardana, Kabir, Dixit, Niharika, Arora, Pooja
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2020
Materias:
Concise Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7678515/
https://www.ncbi.nlm.nih.gov/pubmed/33235861
http://dx.doi.org/10.4103/idoj.IDOJ_499_19
_version_ 1783612171852185600
author Sardana, Kabir
Dixit, Niharika
Arora, Pooja
author_facet Sardana, Kabir
Dixit, Niharika
Arora, Pooja
author_sort Sardana, Kabir
collection PubMed
description
format Online
Article
Text
id pubmed-7678515
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Wolters Kluwer - Medknow
record_format MEDLINE/PubMed
spelling pubmed-76785152020-11-23 A Real-World Analysis of Relapse Rate and Efficacy of a Restricted Monthly Dose of Omalizumab in Recalcitrant Chronic Spontaneous Urticaria in India Sardana, Kabir Dixit, Niharika Arora, Pooja Indian Dermatol Online J Concise Communication Wolters Kluwer - Medknow 2020-09-19 /pmc/articles/PMC7678515/ /pubmed/33235861 http://dx.doi.org/10.4103/idoj.IDOJ_499_19 Text en Copyright: © 2020 Indian Dermatology Online Journal http://creativecommons.org/licenses/by-nc-sa/4.0 This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
spellingShingle Concise Communication
Sardana, Kabir
Dixit, Niharika
Arora, Pooja
A Real-World Analysis of Relapse Rate and Efficacy of a Restricted Monthly Dose of Omalizumab in Recalcitrant Chronic Spontaneous Urticaria in India
title A Real-World Analysis of Relapse Rate and Efficacy of a Restricted Monthly Dose of Omalizumab in Recalcitrant Chronic Spontaneous Urticaria in India
title_full A Real-World Analysis of Relapse Rate and Efficacy of a Restricted Monthly Dose of Omalizumab in Recalcitrant Chronic Spontaneous Urticaria in India
title_fullStr A Real-World Analysis of Relapse Rate and Efficacy of a Restricted Monthly Dose of Omalizumab in Recalcitrant Chronic Spontaneous Urticaria in India
title_full_unstemmed A Real-World Analysis of Relapse Rate and Efficacy of a Restricted Monthly Dose of Omalizumab in Recalcitrant Chronic Spontaneous Urticaria in India
title_short A Real-World Analysis of Relapse Rate and Efficacy of a Restricted Monthly Dose of Omalizumab in Recalcitrant Chronic Spontaneous Urticaria in India
title_sort real-world analysis of relapse rate and efficacy of a restricted monthly dose of omalizumab in recalcitrant chronic spontaneous urticaria in india
topic Concise Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7678515/
https://www.ncbi.nlm.nih.gov/pubmed/33235861
http://dx.doi.org/10.4103/idoj.IDOJ_499_19
work_keys_str_mv AT sardanakabir arealworldanalysisofrelapserateandefficacyofarestrictedmonthlydoseofomalizumabinrecalcitrantchronicspontaneousurticariainindia
AT dixitniharika arealworldanalysisofrelapserateandefficacyofarestrictedmonthlydoseofomalizumabinrecalcitrantchronicspontaneousurticariainindia
AT arorapooja arealworldanalysisofrelapserateandefficacyofarestrictedmonthlydoseofomalizumabinrecalcitrantchronicspontaneousurticariainindia
AT sardanakabir realworldanalysisofrelapserateandefficacyofarestrictedmonthlydoseofomalizumabinrecalcitrantchronicspontaneousurticariainindia
AT dixitniharika realworldanalysisofrelapserateandefficacyofarestrictedmonthlydoseofomalizumabinrecalcitrantchronicspontaneousurticariainindia
AT arorapooja realworldanalysisofrelapserateandefficacyofarestrictedmonthlydoseofomalizumabinrecalcitrantchronicspontaneousurticariainindia

Ejemplares similares